Moreover, some ACE inhibitors (ACEi) or angiotensin receptor blockers (ARB), which are used to treat comorbidities in COVID-19 patients, might increase the level of ACE2 in myocardial cells, theoretically, leading to elevated risk for cardiac injury. This evidence concerns the gene ACE and COVID-19.